For research use only. Not for therapeutic Use.
SOR-C13 TFA, a carboxy-terminal truncated peptide, is a high-affinity TRPV6 antagonist with an IC50 value of 14 nM. TRPV6 is a non-voltage gated calcium channel that is associated with malignancy and poor prognosis in breast cancer. SOR-C13 TFA has anticancer activity[1].
SOR-C13 (i.p.; 400,600, 800 mg/kg; daily; on days 1 to 12) TFA can effectively inhibit the growth of tumor in female NOD/SCID mice with SKOV-3 cell[2].
| Catalog Number | I041396 |
| Molecular Formula | C72H116N20O19.xC2HF3O2 |
| Purity | ≥95% |
| Reference | [1]. S Fu , et al. Erratum to: First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2017 Jun;35(3):397. [2]. Hui Xue, et al. Inhibition of Transient Receptor Potential Vanilloid 6 channel, elevated in human ovarian cancers, reduces tumour growth in a xenograft model. J Cancer. 2018 Aug 6;9(17):3196-3207. |
